SMAD3 and neoplasm: For the first time, we demonstrated that the combination of SMAD3 tumor expression level with host SMAD3-rs745103 genotype could identify smaller groups of patients at significantly higher risk of not responding to nCRT treatment compared to individual molecular parameters.